Be Prepared to Dispense Alternatives to Usual COVID-19 Meds

Shortages of tocilizumab (Actemra) mean you'll see more orders for other COVID-19 treatments.

Tocilizumab has been the go-to add-on to steroids (dexamethasone, etc) for COVID-19. It's because this "IL-6 inhibitor" has the strongest evidence for reducing mortality.

But tocilizumab supplies are low. And it may need to be reserved for other uses where tocilizumab is the only treatment.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote